Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics

- University of Waterloo’s Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon - KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to congratulate Christopher Wilson, PhD, on being recognized by the University of Waterloo’s (“UW”) Faculty of Engineering for his significant contributions to research and scholarship. The award recognizes Dr. Wilson’s research at the Institute for Quantum Computing (“IQC”) at UW. Dr. Wilson’s work explores the use of superconducting quantum electronics for both applications and basic science. His research brings together start-ups, academia and defense sectors in Canada and internationally, and he has secured $13 million in research funding from agencies in Canada, the U.S. and Europe since the start of his career. Dr. Wilson has supervised more than 40 research associates, postdoctoral fellows, PhD students, master’s and undergraduate students, whom he involves in international collaborations. Among his more than 100 refereed publications, 30 high-impact publications have students or postdocs as first authors. His new textbook, Building Quantum Computers, was published by Cambridge University Press in 2024. It was co-authored by IQC past Executive Director, Raymond Laflamme, and IQC PhD Student, Shayan Majady, and is based on their courses on quantum information processing taught at IQC. Greg Lipschitz, Executive Chairman of Firefly, said, “On behalf of everyone here, I would like to extend my sincere congratulations to Dr. Wilson on this amazing achievement. In addition to his outstanding contributions to the advancement of quantum science and technology, Dr. Wilson is a vital member of Firefly’s Advisory Development Board. Most recently, he has been collaborating on an exciting new brain model initiative. We are looking forward to providing more information on that in the near future.” About FireflyFirefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome. Please visit https://fireflyneuro.com/ for more information. Forward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA™ technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the Merger; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor & Media ContactStephen Kilmer(646) 274-3580stephen.kilmer@fireflyneuro.com

Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News